Answer
Hemlibra (emicizumab) should be used during pregnancy only if the potential maternal benefit outweighs the potential fetal risk, considering increased thrombosis risk during pregnancy and after childbirth and the increased risk of disseminated intravascular coagulation associated with several pregnancy complications.
Sources for this answer
- Hemlibra 30 mg/mL and 150 mg/mL Solution for InjectionRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 17Document updated
Sources checked